Year Founded: 2006
Number of Employees: ~500
Key Personnel: Lee Karras, CEO; Barry Lederman, CFO; BJ
Hull, VP and General Manager, Whippany; Maryse LaLiberte,
VP and General Manager, Montreal Operations; Glenn Herring,
VP Technical Operations; Dr. Anthony Qu, VP Pharmaceutical
Halo Pharmaceutical is a contract development and
manufacturing organization that provides scientific, regulatory
and development expertise
as well as a wide spectrum
of manufacturing services to
help customers bring their
products to market quickly,
effectively and on budget.
Halo offers fully integrated
capabilities in a variety of
dosage forms including
tablets, capsules, powders, liquids, creams, sterile and non-
sterile ointments and suppositories.
Halo Pharmaceutical’s capabilities in the areas of tech
transfer, process and product development, production,
scale-up and validation and analytical method development
allow us to partner with clients from development through
commercialization or at any point along the way.
Halo’s specialty is in the manufacture of controlled substances
for both the US and Canadian markets with additional expertise
in abuse deterrent technologies and dosage forms.
Halo Pharma has a wide variety of clients including some of
Halo’s products and services are organized into a variety of
the world’s largest pharmaceutical companies; emerging and
established biotech; specialty pharma; and selected generic
manufacturing companies. Halo’s agility, flexibility and highly-
experienced staff allows it to provide exceptional customer
service on every project.
areas including Pharmaceutical Development, Commercial
Manufacturing, Formulation and Pre-formulation services.
Specializing in all aspects of the CMC dosage form section of the
NDA, Halo’s Pharmaceutical Development services extend from
Phase I through Registration and include Project Management,
Formulation Development and Analytical Development.
Halo’s Commercial Manufacturing capabilities include:
• Controlled Substances (DEA Schedule I – V)
• Extended/Modified Release Tablets/Capsules
• Sustained Release Beads
• Micro and Mini Tablets
• Film Coated Tablets
• Solvent Based Formulations
• Non-Sterile Ointments
• Sterile Ointments
Halo has two locations, one in Whippany, NJ ( 175,000 sq. ft.) and
one in Montreal, Quebec ( 226,000 sq. ft.). The Whippany facility is
capable of developing, manufacturing and finishing oral dosages,
liquids, suppositories and sterile ointments including the ability to
do all dosage forms for DEA Schedule I-V. The facility in Montreal,
Quebec specializes in development through commercialization
of liquids, ointments, creams, suppositories and oral solid dosage
forms. Both facilities have excellent regulatory histories, with the
Whippany facility approved by FDA/MHRA and the Montreal
facility approved by Health Canada/FDA.
Halo Pharmaceutical, Inc.
30 North Jefferson Road
Whippany, NJ 07981
17800, rue Lapointe
Canada J7J 1P3